Dogs get cancer, just like humans. Scientists at the University of Veterinary Medicine, Vienna are now exploring the molecular basis of cancer progression in canine cell lines. Modern cancer therapy has been revolutionized with the introduction of new drugs, so-called ‘targeted drugs’, but the basis for the application of these new agents in cancer therapy is a deep understanding of the molecular mechanisms of the disease, even with pets. Now a research team led by Sabine Macho-Maschler has investigated the activation of genetic regulatory mechanisms in canine cells and found both matches as well as differences compared to man.
Almost every second dog above the age of ten years develops cancer. Modern tumor therapy combines surgery, radiation therapy and novel drug treatment options. While surgery and radiotherapy ensure adequate treatment for all animals at the University of Veterinary Medicine, Vienna, there is a growing gap in the treatment with modern therapeutics.
The reason for this is that modern targeted agents are based on specific molecular genetics findings, which are not easy to transfer to dogs from humans or the preferred animal model in cancer research, the mouse. So to make modern cancer drugs also accessible to our four-legged friends requires comparative research into the molecular basis of cancer in dogs.
Molecular causes constitute an important basis for modern treatment concepts
Our understanding of the molecular and cellular causes that are responsible for the development of cancer has grown strongly in recent years. This knowledge aids us in combating cancer cells with a growing number of new drugs.
However, since cancer may manifest itself differently in each patient, an extensive molecular study of the existing mutations in cancer cells is an important prerequisite for successful therapy. This is because the targeted agents can only actually help when the cancer cells possess the corresponding molecular structures against which the drug is designed to act. The success of treatment with targeted drugs requires a molecular diagnosis, as basis for the so-called ‘personalized medicine’ in cancer research.
Investigation into the molecular mechanisms of metastasis in canine cells
A research team at the Unit of Molecular Genetics have investigated an important process in the molecular genetics of cancer development in canine cell lines. These cell lines have long been used by researchers to analyze pathological processes and now were analyzed for changes in the expression of several RNA-species using next generation sequencing.
"Cancer researchers have been working for many years on the transition of epithelial tumor cells into the more aggressive mesenchymal state. Important gene switches could be identified in this process with potential for use as therapeutic targets: these gene products could be targeted with novel therapeutics”, explained Macho-Maschler, who headed the now published study. Research on epithelial-mesenchymal transition (EMT) has so far mainly focused on cells of mice and humans and showed how certain signaling pathways cooperate to allow cancer cells metastasis. Metastases are formed when the originally sedentary cancer cells obtain certain properties, which allow them to migrate into another organ and to form a new tumor there.
“In the majority of cases it is the metastases that cost the patient’s live, as the original tumor can often be well controlled by radiation and surgery," emphasized Mathias Müller, head of the Institute for Animal Breeding and Genetics. "We are interested in what is going on at the molecular level during metastasis, as it is likely that we can use this knowledge for the successful treatment of metastases."
The basis for further research has been laid
The molecular analysis of EMT is considered by researchers as a model for the acquisition of the ability to metastasize. The TGF-beta pathway has for a long time been recognized as a central switch in this process. Macho-Maschler expressed her satisfaction with the many similarities seen in the comparative analysis of results for canine, human and mouse cells. "TGF-beta, for example, also plays an important role in dogs, but there are also interesting variations," reports Macho-Maschler. Her recent BMC Genomics publication is filled with long lists of RNAs that are regulated during EMT.
These findings should serve as a basis for further analysis. Macho-Maschler is skeptical as to whether their research can improve the treatment of dogs with cancer in the near future. "Our newly published results are like a catalogue, perhaps an important requirement for new approaches and ideas. Ultimately, we do not even know whether many of the new drugs actually act in canine cells. There are, for example, targeted drugs which act only in humans but not in mice" says Macho-Maschler to dampen unrealistic expectations.
In humans, a much more comprehensive catalogue was completed this year; "The Cancer Genome Atlas" makes available to researchers the essential information contained within 11,000 genetically analyzed patient samples (cancergenome.nih.gov). It is an important resource, which enables researchers quickly and reliably to check the frequency of certain genetic changes in a cancer. The catalogue published by Macho-Maschler is naturally not comparable with the TCGA, but it is a first important step in the same direction for canine cancer.
The article “High-throughput mRNA and miRNA profiling of epithelial-mesenchymal transition in MDCK cells”, by Priyank Shukla, Claus Vogl, Barbara Wallner, Doris Rigler, Mathias Müller and Sabine Macho-Maschler was published in BMC Genomics. doi:10.1186/s12864-015-2036-9 http://www.biomedcentral.com/1471-2164/16/944
About the University of Veterinary Medicine Vienna
The University of Veterinary Medicine Vienna (Vetmeduni Vienna) is one of the leading veterinary, academic and research facilities in Europe. Its main focus is on the research fields of animal health, food safety, animal husbandry and animal welfare as well as biomedical fundamentals. The Vetmeduni Vienna has 1,300 employees and is currently training 2,300 students. The campus in Floridsdorf, Vienna has five university hospitals and numerous research institutions at its disposal. Two research institutes at Wilhelminenberg, Vienna and a Teaching and Research in Lower Austria also belong to the Vetmeduni Vienna. In 2015, the Vetmeduni Vienna is celebrating the 250th anniversary of its founding. http://www.vetmeduni.ac.at
Dr. Sabine Macho-Maschler
University of Veterinary Medicine Vienna
Institute for Animal Breeding and Genetics
T +43 1 25077- 5627
Science Communication / Corporate Communications
University of Veterinary Medicine Vienna (Vetmeduni Vienna)
T +43 1 25077-1153
Dr. Susanna Berger | Veterinärmedizinische Universität Wien
Multi-institutional collaboration uncovers how molecular machines assemble
02.12.2016 | Salk Institute
Fertilized egg cells trigger and monitor loss of sperm’s epigenetic memory
02.12.2016 | IMBA - Institut für Molekulare Biotechnologie der Österreichischen Akademie der Wissenschaften GmbH
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.
Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy